- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06412042
Probiotic in Infant Growth, Allergy and Immunity Study
May 10, 2024 updated by: Wecare Probiotics Co., Ltd.
Prospective, Placebo-Controlled, Randomized Double-Blind Clinical Study on the Intervention of Animal-Derived Probiotic in Infant Growth and Development, Allergy Incidence, and Immune Function
To evaluate the intervention effects of Bifidobacterium animalis subsp.
lactis strain BLa80 in promoting growth and development (including gut microbiota and physical growth and development) of healthy infants and young children across different age groups, enhancing immune function, improving allergy incidence, and analyzing the safety of BLa80 in relation to infant growth and development, allergy incidence, and gut microbiota.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Vicky Achmad Ginanjar, bachelor
- Phone Number: +62 +62 21 7695513, 7515932
- Email: vicky.achmad@equilab-int.com
Study Contact Backup
- Name: Natalina Soesilawati, Dr.
- Phone Number: +62 21 88324366
Study Locations
-
-
Jakarta 10430
-
Jakarta Pusat, Jakarta 10430, Indonesia, 10430
- Fakultas Kedokteran Universitas Indonesia
-
Contact:
- Natalina Soesilawati
- Phone Number: +62 +62 21 7695513, 7515932
- Email: ec_fkui@yahoo.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy infants and young children born at 37 to 42 weeks of gestation through both artificial breastfeeding, with a birth weight greater than or equal to 2500 g and less than 4000 g, regardless of gender
- Infants and young children whose mothers do not have diagnosed metabolic disorders such as diabetes and are not afflicted with communicable diseases such as hepatitis B or HIV
- Enrollment will be stratified into three age groups: 0-6 months, 6-12 months, and 12-36 months
- Consent from parents or primary caregivers of infants and young children to collect faecal samples during the study
- No clinically diagnosed allergic diseases at the time of enrolment (including but not limited to eczema, asthma, allergic colitis, allergic rhinitis, pollen allergies, etc.)
- Infants and young children with a medical record established at local maternal and child health care hospital's paediatrics department, undergoing regular check-ups, and following feeding advice and guidance from pediatricians
- Assurance from family members or primary caregivers not to administer additional probiotic products (including formula milk containing probiotics) to infants and young children during the intervention period.
Exclusion Criteria:
Healthy infants and young children aged 0-6 months:
- Infants with a history of asphyxia at birth or a history of NICU hospitalization
- Infants born with congenital defects or abnormalities
- Infants whose mother had pregnancy-related conditions such as gestational hypertension, pre-eclampsia or eclampsia, gestational diabetes, cholestasis of pregnancy, or other high-risk obstetric factors, as well as a history of alcohol or drug abuse during pregnancy
- Infants who have used antibiotics within 2 weeks prior to enrollment
- Infants who have had specific diseases affecting growth and development within 1 month prior to enrollment (e.g., pneumonia, severe diarrhea, severe constipation, severe cow's milk protein allergy, malnutrition, gastrointestinal surgery, severe congenital heart disease, epilepsy, cerebral palsy, developmental delay, confirmed genetic metabolic disorders, chromosomal disorders, genetic diseases, etc.)
- Infants with severe primary diseases affecting other important organs or systems such as the heart, liver, kidney, hematopoietic system, etc.
- Infants who have used investigational drugs or participated in other clinical studies before screening
- Infants who have consumed probiotic products within 1 month prior to enrollment (calculated from birth to enrollment for infants aged <1 month)
- Infants who have used immunosuppressive drugs (such as glucocorticoids, immunosuppressants) before enrollment
- Infants with known allergies to the ingredients of probiotic products
- Children who require hospitalization for treatment due to malnutrition
- Other reasons that researchers consider as unsuitable for participation in the clinical trial, such as those that could affect efficacy evaluation or individuals with poor compliance
Infants and young children aged 6-12 months with good health
- Infants who have used antibiotics within 2 weeks prior to enrollment
- Infants who have had specific diseases affecting growth and development within the 1 month prior to enrollment (Infants who have had specific diseases affecting growth and development within 1 month prior to enrollment (e.g., pneumonia, severe diarrhea, severe constipation, severe cow's milk protein allergy, malnutrition, gastrointestinal surgery, severe congenital heart disease, epilepsy, cerebral palsy, developmental delay, confirmed genetic metabolic disorders, chromosomal disorders, genetic diseases, etc.)
- Infants with severe primary diseases affecting other important organs or systems such as the heart, liver, kidney, hematopoietic system, etc.
- Infants who have used investigational drugs or participated in other clinical studies within 3 months prior to screening
- Infants who have consumed probiotic products within 1 month prior to enrollment
- Infants who have used immunosuppressive drugs (such as glucocorticoids, immunosuppressants) before enrollment
- Infants with known allergies to the ingredients of probiotic products
- Children who require hospitalization for treatment due to malnutrition
- Other reasons that researchers consider as unsuitable for participation in the clinical trial, such as those that could affect efficacy evaluation or individuals with poor compliance
Infants and young children aged 12-36 months with good health
- Infants who have used antibiotics within 2 weeks prior to enrollment
- Infants who have had specific diseases affecting growth and development within the 1 month prior to enrollment, such as pneumonia, severe diarrhea, severe constipation, severe cow's milk protein allergy, malnutrition, gastrointestinal surgery, severe congenital heart disease, epilepsy, cerebral palsy, developmental delay, confirmed genetic metabolic disorders, chromosomal disorders, genetic diseases, etc.
- Infants with severe primary diseases affecting other important organs or systems such as the heart, liver, kidney, hematopoietic system, etc.
- Infants who have used investigational drugs or participated in other clinical studies within 3 months prior to screening
- Infants who have consumed probiotic products within 1 month prior to enrollment
- Infants who have used immunosuppressive drugs (such as glucocorticoids, immunosuppressants) before enrollment
- Infants with known allergies to the ingredients of probiotic products
- Children who require hospitalization for treatment due to malnutrition
- Other reasons that researchers consider as unsuitable for participation in the clinical trial, such as those that could affect efficacy evaluation or individuals with poor compliance
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Probiotic BLa80
Participants receive one sachet per day containing probiotic BLa80 and maltodextrin (Day 0 to Day 84).
|
Collect baby fecal samples, test for 16S rRNA, and analyze changes in the gut microbiota before and after supplementation.
|
Placebo Comparator: Maltodextrin
Participants receive one sachet per day containing maltodextrin only, serving as the placebo (Day 0 to Day 84).
|
Collect baby fecal samples, test for 16S rRNA, and analyze changes in the gut microbiota before and after supplementation.
|
No Intervention: Blank
Participants in this arm will not receive any intervention or placebo.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in gut microbiota
Time Frame: 84 days
|
Collect patient fecal samples, test for 16S rRNA.
|
84 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Natalina Soesilawati, Dr., Karya Medika II Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 15, 2024
Primary Completion (Estimated)
September 15, 2024
Study Completion (Estimated)
September 25, 2024
Study Registration Dates
First Submitted
April 25, 2024
First Submitted That Met QC Criteria
May 10, 2024
First Posted (Actual)
May 14, 2024
Study Record Updates
Last Update Posted (Actual)
May 14, 2024
Last Update Submitted That Met QC Criteria
May 10, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WK2024006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Probiotic BLa80
-
Wecare Probiotics Co., Ltd.Completed
-
Wecare Probiotics Co., Ltd.Completed
-
Wecare Probiotics Co., Ltd.Not yet recruitingAlcohol Drinking, Adult Disease
-
King's College Hospital NHS TrustCompleted
-
Fudan UniversityInner Mongolia Yili Industrial Group Co., LtdCompletedObesity | AdiposityChina
-
Maastricht University Medical CenterCompleted
-
Centros de Investigación de Nutrición y SaludNutribioticaCompletedFunctional ConstipationSpain
-
Universiti Kebangsaan Malaysia Medical CentreUnknownHypertension | Obesity | Type 2 Diabetes Mellitus | HyperlipidemiaMalaysia
-
Fundació Sant Joan de DéuCompleted
-
University of LeedsUnknown